3 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Neoplasm Malignant: new trials by email Literature Review of Neoplasm Malignant trials Research Report on Neoplasm Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) Calderasib, Cetuximab - Neoplasm Malignant | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 150 | 2025-12-04 | 2026-10-07 |
| Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study FOLFOXIRI Protocol - Neoplasm Malignant, Colon Cancer Stage 4 | Phase 2 | Unknown | Al-Azhar University | 60 | 2024-08-17 | 2024-08-28 |
| A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors STRO-002 - Neoplasm Malignant | Phase 1 / Phase 2 | Completed | Tasly Pharmaceutical Group Co., Ltd | 19 | 2023-11-08 | 2026-04-06 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Pembrolizumab, Belzutifan, Lenvatinib - Neoplasm Malignant | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 730 | 2021-08-18 | 2025-04-06 |
| A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification SAR125844 - Neoplasm Malignant | Phase 2 | Completed | Sanofi | 1 | 2015-11-01 | 2016-03-23 |
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen SAR245408, SAR245409 - Neoplasm Malignant | Phase 1 / Phase 2 | Completed | Sanofi | 61 | 2012-07-20 | 2022-04-19 |
Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Neoplasms by Site (2) · Adenocarcinoma (1) · Adenoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Colonic Diseases (1) · Colorectal Neoplasms (1)
Cetuximab (2) · pembrolizumab (2) · Bevacizumab (1) · Docetaxel (1) · FOLFOXIRI protocol (1) · Leucovorin (1) · Levoleucovorin (1) · Panitumumab (1) · SAR125844 (1) · XL147 (1) · XL765 (1) · belzutifan (1) · lenvatinib (1)
Merck Sharp & Dohme LLC (2) · Sanofi (2) · Al-Azhar University (1) · NuCana plc (1) · Tasly Pharmaceutical Group Co., Ltd (1)
Belgium (3) · France (3) · Spain (3) · United States (3) · Australia (2) · Chile (2) · China (2) · Israel (2) · South Korea (2) · United Kingdom (2) · Canada (1) · Denmark (1) · Egypt (1) · Germany (1) · Greece (1)
PMID 10744089, PMID 11247898, PMID 15175435, PMID 15870084, PMID 16943526, PMID 17470860, PMID 18316791, PMID 19097774, PMID 19339720, PMID 19755046, PMID 21090969, PMID 24138831, PMID 26818619, PMID 37062953
2014 (1), 2023 (1), 2025 (1)